Ran Frenkel

KPTI

Ran Frenkel serves as EVP, Chief Dev. Officer at Karyopharm Therapeutics Inc. (KPTI). This page tracks their complete SEC Form 4 insider trading history including stock purchases and sales.

Total Buys

0 trades

$0.00

Total Sells

3 trades

$72.2K

Net Position

Net Seller

$72.2K

Companies Traded

KPTI

Active Period

Feb 2022 – Mar 2022

3 total trades

Most Recent

Sell KPTI

Mar 2, 2022 · $17.0K

Ran Frenkel's Insider Trading at Karyopharm Therapeutics Inc. (KPTI)

Buys

0 · $0.00

Sells

3 · $72.2K

Total Shares Bought

Total Shares Sold

6,583

KPTI Price Chart

Loading chart...

Date	Type	Shares	Avg Price	Value	Shares After
Mar 2, 2022	Sell	1,663	$10.24	$17.0K	168,290
Feb 22, 2022	Sell	2,929	$12.12	$35.5K	101,703
Feb 9, 2022	Sell	1,991	$9.86	$19.6K	104,632

Related Insiders

Michael Mano

SVP, General Counsel&Secretary

KPTISell · Mar 3, 2026

Sohanya Roshan Cheng

officer: EVP & Chief Commercial Officer

KPTISell · Mar 3, 2026

Stuart Poulton

officer: EVP, Chief Development Officer

KPTISell · Mar 3, 2026

Reshma Rangwala

officer: EVP & Chief Medical Officer

KPTISell · Mar 3, 2026

Richard A. Paulson

President and CEO

KPTISell · Mar 3, 2026

Lori Macomber

officer: EVP, CFO & Treasurer

KPTISell · Feb 4, 2026

Kristin Abate

officer: Chief Accounting Officer

KPTISell · Jan 29, 2026

Explore More Insider Trading Data

KPTI Insider Trading Activity

View all insider trades at Karyopharm Therapeutics Inc.

Healthcare Sector Insider Trades

See insider activity across healthcare stocks

Latest Insider Buys

Most recent insider purchases across all stocks

CEO Stock Purchases

Track CEO buying activity